Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2009 3
2010 1
2014 1
2015 1
2016 2
2017 5
2018 1
2020 3
2021 3
2022 5
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 in adults: test menu for hospital blood science laboratories.
O'Shea PM, Lee GR, Griffin TP, Tormey V, Hayat A, Costelloe SJ, Griffin DG, Srinivasan S, O'Kane M, Burke CM, Faul J, Thompson CJ, Curley G, Tormey WP. O'Shea PM, et al. Among authors: hayat a. Ir J Med Sci. 2020 Nov;189(4):1147-1152. doi: 10.1007/s11845-020-02252-0. Epub 2020 May 18. Ir J Med Sci. 2020. PMID: 32424603 Free PMC article. Review.
Advances in the management of myeloma: an update.
Meenaghan T, Hayat A, Walpole G, Dowling M. Meenaghan T, et al. Among authors: hayat a. Br J Nurs. 2023 Sep 21;32(17):S4-S12. doi: 10.12968/bjon.2023.32.17.S4. Br J Nurs. 2023. PMID: 37737854
Recurrent clotted blood specimens: a sticky dilemma.
McAuliffe E, Hayat A, Renton B. McAuliffe E, et al. Among authors: hayat a. Br J Hosp Med (Lond). 2023 Dec 2;84(12):1. doi: 10.12968/hmed.2023.0223. Epub 2023 Dec 4. Br J Hosp Med (Lond). 2023. PMID: 38153018 Free article. No abstract available.
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis.
Harrison C, Heidel FH, Vannucchi AM, Kiladjian JJ, Hayat A, Passamonti F, Conneally E, Kindler T, Martino B, Lipka DB, Stefanelli T, Roussou P, Germano D, Ewan J, Ribrag V. Harrison C, et al. Among authors: hayat a. Hemasphere. 2022 Aug 2;6(8):e757. doi: 10.1097/HS9.0000000000000757. eCollection 2022 Aug. Hemasphere. 2022. PMID: 35935608 Free PMC article. No abstract available.
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.
Mohamed SA, Duffy A, McInerney V, Krawczyk J, Hayat A, Naughton S, Finnerty A, Holohan M, Liew A, Tubassam M, Walsh SR, O'Brien T, Howard L. Mohamed SA, et al. Among authors: hayat a. Cytotherapy. 2022 Dec;24(12):1259-1267. doi: 10.1016/j.jcyt.2022.07.002. Epub 2022 Aug 20. Cytotherapy. 2022. PMID: 35999133 Free article.
TP53 Mutations Identified Using NGS Comprise the Overwhelming Majority of TP53 Disruptions in CLL: Results From a Multicentre Study.
Catherwood MA, Wren D, Chiecchio L, Cavalieri D, Donaldson D, Lawless S, ElHassadi E, Hayat A, Cahill MR, O'Shea D, Sargent J, Stewart P, Maurya M, Quinn J, Murphy P, de Castro DG, Mills K, Cross NCP, Forconi F, Iyengar S, Schuh A, Thornton P. Catherwood MA, et al. Among authors: hayat a. Front Oncol. 2022 Jun 28;12:909615. doi: 10.3389/fonc.2022.909615. eCollection 2022. Front Oncol. 2022. PMID: 35837095 Free PMC article.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Rampotas A, Wilson MR, Lomas O, Denny N, Leary H, Ferguson G, McKay P, Ebsworth T, Miller J, Shah N, Martinez-Calle N, Bishton M, Everden A, Tucker D, El-Hassad E, Hennessy B, Doherty D, Prideaux S, Faryal R, Hayat A, Keohane C, Marr H, Gibb A, Pocock R, Lambert J, Lacey R, Elmusharaf N, Clifford R, Eyre TA. Rampotas A, et al. Among authors: hayat a. Br J Haematol. 2021 Jul;194(2):365-377. doi: 10.1111/bjh.17513. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33959947
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Ribrag V, Lee ST, Rizzieri D, Dyer MJS, Fayad L, Kurzrock R, Andritsos L, Bouabdallah R, Hayat A, Bacon L, Jiang Y, Miah K, Delafont B, Hamid O, Anyanwu S, Martinez P, Hess B. Ribrag V, et al. Among authors: hayat a. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):309-317.e3. doi: 10.1016/j.clml.2020.12.012. Epub 2020 Dec 17. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33632668 Free article. Clinical Trial.
24 results